Key result
Prothrombin activation fragment (F1.2) showed a significantly higher correlation with S-100beta (a marker of thromboembolic events) compared to INR and aPTT (P<0.0001) in patients with VADs.
Why the study?
Does prothrombin activation fragment (F1.2) monitoring better predict thromboembolic events compared to standard coagulation assays in patients with left-sided VADs?
Observational (n=31)
Does prothrombin activation fragment (F1.2) monitoring better predict thromboembolic events compared to standard coagulation assays in patients with left-sided VADs?
F1.2 levels may provide a more accurate surrogate predictor of thromboembolic events than conventional coagulation assays (INR/aPTT) in patients with left-sided VADs.
Prothrombin time, expressed as international normalized ratio (INR) and activated partial thromboplastin time (aPTT), are standard methods of monitoring coumadin and heparin administration. Prothrombin activation fragment (F1.2) is an index of in vivo thrombin generation. We hypothesized that F1.2 would provide a better surrogate of thromboembolism risk than standard coagulation assays during ventricular assist device (VAD) support. INR, PTT and F1.2 were analyzed in 31 patients after implantation of a left-sided VAD daily during hospitalization and weekly after discharge. Thromboembolic events (TE) were defined by evidence of neurological injury revealed by plasma levels of S-100beta. The relationships between F1.2, INR for patients on coumadin and aPTT for patients on heparin were evaluated from 1250 observations of blood samples. S-100beta was positively correlated with F1.2, but not with INR and aPTT. Correlation between S-100beta and F1.2 is significantly higher than with the other two markers (P<0.0001). Higher values of aPTT and INR were not associated with TE. Compared to conventional coagulation assays, the F1.2 level provides a single endpoint that is a more accurate predictor of TE after VAD implantation. Further trials that incorporate the F1.2 marker into anticoagulation algorithms may help reduce adverse events in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2007) conducted an observational in Patients with left-sided ventricular assist devices (VAD) (n=31). Prothrombin activation fragment (F1.2) vs. Standard coagulation assays (INR and aPTT) was evaluated on Correlation between S-100beta (marker of thromboembolic events) and coagulation markers (p=<0.0001). Prothrombin activation fragment (F1.2) showed a significantly higher correlation with S-100beta (a marker of thromboembolic events) compared to INR and aPTT (P<0.0001) in patients with VADs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: